22.95

0.17% -0.088

Bridgebio Pharma Inc (BBIO)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BBIO? Forum Prognose

Schlusskurs vom Vortag:

$23.04

Offen:

$23.04

24-Stunden-Volumen:

203.54K

Relative Volume:

0.10

Marktkapitalisierung:

$4.35B

Einnahmen:

$219.12M

Nettoeinkommen (Verlust:

$-453.82M

KGV:

-5.8851

EPS:

-3.9

Netto-Cashflow:

$-419.68M

1W Leistung:

-4.60%

1M Leistung:

-8.59%

6M Leistung:

-21.45%

1J Leistung:

-18.76%

1-Tages-Spanne:

$22.90

$23.42

1-Wochen-Bereich:

$21.72

$24.30

52-Wochen-Spanne:

$21.62

$44.32

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Firmenname

Bridgebio Pharma Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

(650) 391-9740

Adresse

3160 PORTER DR., PALO ALTO, CA

Mitarbeiter

556

Twitter

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

BBIO's Discussions on Twitter

Vergleichen Sie BBIO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BBIO	22.96	4.35B	219.12M	-453.82M	-419.68M	-3.90
VRTX	446.39	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	739.76	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	584.60	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.09	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.30	24.49B	3.30B	-501.07M	1.03B	11.54

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-10-03	Eingeleitet	Oppenheimer	Perform
2024-09-04	Eingeleitet	Piper Sandler	Overweight
2024-03-21	Fortgesetzt	Raymond James	Outperform
2024-01-31	Eingeleitet	BMO Capital Markets	Market Perform
2023-12-08	Eingeleitet	Wells Fargo	Overweight
2023-11-07	Eingeleitet	Citigroup	Buy
2023-10-24	Eingeleitet	Cantor Fitzgerald	Overweight
2023-07-18	Herabstufung	Jefferies	Buy → Hold
2023-04-19	Eingeleitet	Evercore ISI	Outperform
2023-02-06	Eingeleitet	Cowen	Outperform
2021-12-27	Bestätigt	Mizuho	Buy
2021-12-27	Bestätigt	SVB Leerink	Outperform
2021-09-10	Hochstufung	BofA Securities	Neutral → Buy
2021-05-21	Eingeleitet	UBS	Buy
2021-03-22	Bestätigt	Goldman	Buy
2021-02-22	Fortgesetzt	JP Morgan	Overweight
2021-02-09	Fortgesetzt	Goldman	Buy
2021-01-11	Bestätigt	H.C. Wainwright	Buy
2020-12-10	Bestätigt	H.C. Wainwright	Buy
2020-06-25	Eingeleitet	BofA/Merrill	Neutral
2020-05-19	Eingeleitet	BTIG Research	Buy
2020-04-13	Eingeleitet	H.C. Wainwright	Buy
2020-02-19	Eingeleitet	Mizuho	Buy
2019-07-26	Eingeleitet	Raymond James	Outperform
2019-07-22	Eingeleitet	BMO Capital Markets	Outperform
2019-07-22	Eingeleitet	Goldman	Buy
2019-07-22	Eingeleitet	JP Morgan	Overweight
2019-07-22	Eingeleitet	Jefferies	Buy
2019-07-22	Eingeleitet	Piper Jaffray	Overweight
2019-07-22	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten

Nov 20, 2024

BBIO (BridgeBio Pharma) 5-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Insider Sell Alert: Brian Stephenson Sells Shares of BridgeBio P - GuruFocus.com

Nov 20, 2024

BridgeBio Pharma CEO Neil Kumar sells $613,825 in stock By Investing.com - Investing.com South Africa

Nov 20, 2024

BridgeBio Pharma CEO Neil Kumar sells $613,825 in stock - Investing.com

Nov 20, 2024

BridgeBio Pharma CFO Brian Stephenson sells shares worth $93,136 - Investing.com

Nov 20, 2024

Bridge Bio Study Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes in ATTR-CM - DocWire News

Nov 20, 2024

Nov 19, 2024

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market - Yahoo Finance

Nov 19, 2024

399,781 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Bought by First Turn Management LLC - MarketBeat

Nov 19, 2024

The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically - Yahoo Finance

Nov 19, 2024

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analysts Are More Bearish Than They Used To Be - Simply Wall St

Nov 19, 2024

Royce & Associates LP Invests $3.11 Million in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat

Nov 19, 2024

Nov 18, 2024

BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director - BioSpace

Nov 18, 2024

Open-Label Extension Data Confirms Sustained Benefit of - GlobeNewswire

Nov 18, 2024

BridgeBio's Acoramidis Shows 36% Mortality Reduction in ATTR-CM Trial Extension | BBIO Stock News - StockTitan

Nov 18, 2024

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL - The Bakersfield Californian

Nov 18, 2024

BridgeBio Pharma Announces Publication in the New England - GlobeNewswire

Nov 18, 2024

BBIO FY2024 EPS Estimate Reduced by Cantor Fitzgerald - MarketBeat

Nov 18, 2024

Nov 17, 2024

Shareholders in BridgeBio Pharma (NASDAQ:BBIO) have lost 44%, as stock drops 12% this past week - Simply Wall St

Nov 17, 2024

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives $47.57 Average Price Target from Brokerages - MarketBeat

Nov 17, 2024

Nov 15, 2024

Scotiabank Boosts BridgeBio Pharma (NASDAQ:BBIO) Price Target to $45.00 - MarketBeat

Nov 15, 2024

Leerink Partnrs Expects Weaker Earnings for BridgeBio Pharma - MarketBeat

Nov 15, 2024

Nov 14, 2024

BridgeBio: 2 Weeks Until Major Drug Approval Catalyst — A Buy, With Caveats (BBIO) - Seeking Alpha

Nov 14, 2024

Leerink Partnrs Has Negative Outlook of BBIO FY2028 Earnings - MarketBeat

Nov 14, 2024

BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 14, 2024

Nov 13, 2024

BridgeBio Pharma Reports Quarterly Loss Amid Restructuring - TipRanks

Nov 13, 2024

Nov 12, 2024